CNMDCONMED Corporation
Price
-11%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: growth
Quality mixed, no red flags, undemanding price, growth fading, the market undecided.
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. The Company’s 3,900 employees distribute its products worldwide from three primary manufacturing locations.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
CONMED Corporation (CNMD) reported revenue of $343M in Q2 2026 (quarter ended Jun 30, 2026), up 0.3% from the same quarter a year earlier. That came with a gross margin of 57% and net income of $23M (6.7% of revenue). For the full year FY2025, revenue was $1.37B (+5.2% year on year) and net income $47M. Its largest region in Q2 2026 was United States at $52M, 34% of the disclosed total, ahead of EMEA at 26%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jun 17, 2026On June 17, 2026, CONMED Corporation (the “Company”) announced that John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning July 15, 2026 (the “Effective Date”)Director or officer change · Form 8-K
- Jun 4, 2026On June 3, 2026, CONMED Corporation, a Delaware corporation (“CONMED”), entered into separate, privately negotiated purchase agreements (the “Purchase Agreements”) with certain holders of its 2.25% Convertible Senior Notes due 2027 (the “Notes”)Material agreement entered · Form 8-K
- Jun 1, 2026On May 27, 2026, CONMED Corporation, a Delaware corporation (“CONMED”) entered into the First Omnibus Amendment and Increased Facility Activation Notice (the “First Amendment”), among CONMED and its subsidiary Linvatec Nederland B.V., a Netherlands private limited company ( besloten vennootschap ), as borrowers …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $152.3MThe company’s own SEC segment disclosure.
- United States$51.7M34%
- EMEA$40.3M26%
- Asia Pacific$36.6M24%
- Americasexcludingthe United States$23.8M16%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.